Products
Biocon launches Eylea biosimilar launches to US market
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Pipeline
Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study
US 510(k) study to evaluate glaucoma drainage device for IOP reduction among OAG patients who failed previous medical and surgical treatment.
Pipeline
Claris Bio raises $118M to advance first-ever LSCD therapy
Financing to support ongoing and planned clinical trials evaluating CSB-001 (oremepermin alfa ophthalmic solution) as a topical ocular biologic eye drop.
Pipeline
Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt
Findings released at ASRS highlight an 80% reduction in key protein implicated in Stargardt disease after 2 years.
Research
Pediatric cataract surgery carries greater endophthalmitis risk
New IRIS Registry data shows risk nearly three times that of adults, signaling a need for tighter perioperative vigilance in pediatric cases.
Research
ICO partners with Deya Imaging on AI model training study
Platform features a patient smartphone app and AI-powered “doctor hub” portal to asynchronously manage and treat anterior segment eye diseases.
Products
EVOQ Technologies receives US patent for mobile retinal function testing
Patent protection covers the SmartERG, a full-field ERG/VEP system that delivers visual stimulation and wirelessly records ocular electrophysiological responses.
Products
FDA recalls nearly 12M Rohto cooling eye drop products
Agency classifies nationwide Class II recall after identifying several products sold under the Rohto name connected to a potential risk for sterility issues.
Research
Oral health may be key in protecting vision, new findings suggest
Periodontal disease associated with higher risk of developing eye conditions, adding to growing evidence that oral health may influence overall health far beyond the mouth.
Research
Latest CLI data finds soft contact lens profits surpass glasses
See Tomorrow initiative’s topline data offers a sneak peek of results from the reported first-ever analysis of CL profitability in the United States.
Research
Adverum reports 5-year extension data on wet AMD gene therapy
At ASRS 2026, the OPTIC extension finds a single Ixo-vec injection led to a 87% cumulative reduction in annualized anti-VEGF injections.
Pipeline
FDA forms advisory committee to review Sydnexis's low-dose atropine
Federal agency to discuss phase 3 clinical data supporting SYD-101 for the treatment of pediatric progressive myopia following NDA rejection.
Business
Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles
Leadership changes are underway in the eyecare space—and we’ve got the latest.
Products
FDA approves Outlook's LYTENAVA for wet AMD
The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.
Research
Researchers identify higher post-cataract TED risk in patients with thyroid disease
Patients demonstrate up to 51% higher risk of developing TED in the year after surgery, with hyperthyroid patients facing more than double the risk.
Pipeline
Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop
Pending FDA review, Nicox’s NO-donating bimatoprost formulation could receive approval and commercially launch by the end of 2027.
Products
Orasis adds free first fill, in-office dispensing for QLOSI
Two new access routes let ECPs start patients on prescription-based presbyopia drop, without routing through a direct-to-patient pathway.
Products
iBlink app targets dry eye relief with real-time blink monitoring
Eye health app seeks to address digital eye strain symptoms via webcam-based tracking and gentle on-screen reminders.
Pipeline
Dompé begins enrollment for phase 3 trial on NAION intranasal therapy
Intranasal cenegermin takes another step towards being the first FDA-approved treatment for NAION.
Research